Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 6/20 | 0.51 |
| ▸ | NPFFR2 | Q9Y5X5 | 6/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22962212 | 0.90 | NPFFR1 (0.46) | NPFFR1NPFFR2SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL34473862 | 0.89 | NPFFR1 (0.48) | NPFFR1NPFFR2SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL22961965 | 0.89 | CYP2D6 (0.50) | NPFFR1NPFFR2ALDH1A1CYP2D6KMT2A | |
| SCHEMBL22962046 | 0.89 | NPFFR1 (0.45) | NPFFR1NPFFR2SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL29862994 | 0.88 | NPFFR1 (0.51) | NPFFR1NPFFR2SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL13738114 | 0.88 | NPFFR1 (0.51) | NPFFR1NPFFR2SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL23120819 | 0.85 | NPFFR1 (0.53) | NPFFR1NPFFR2SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL22961966 | 0.85 | NPFFR1 (0.53) | NPFFR1NPFFR2SIGMAR1ALDH1A1CYP2D6 | |
| SCHEMBL22962159 | 0.84 | NPFFR1 (0.48) | NPFFR1NPFFR2ALDH1A1CYP2D6KMT2A | |
| SCHEMBL7578999 | 0.81 | NPFFR1 (0.55) | NPFFR1NPFFR2ALDH1A1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| WO-2021026492-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | Humanwell Pharmaceutical US (US) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040150-A1 | KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS | OPRK1, OPRL1, OPRD1 | NPFFR1 46/4885NPFFR2 50/4885IDO1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.